Published online Sep 15, 2015. doi: 10.4251/wjgo.v7.i9.148
Peer-review started: March 22, 2015
First decision: July 1, 2015
Revised: July 6, 2015
Accepted: July 29, 2015
Article in press: August 3, 2015
Published online: September 15, 2015
Processing time: 179 Days and 18.2 Hours
In patients with metastatic colorectal cancer, the liver is the most common site of metastatic disease. In patients with liver-dominant disease, consideration needs to be given to locoregional treatments such as hepatic arterial infusion chemotherapy, transarterial chemoembolisation and selective internal radiation therapy because hepatic metastases are a major cause of liver failure especially in chemorefractory disease. In this review we provide insights on the published literature for locoregional treatment of liver metastases in metastatic colorectal cancer.
Core tip: Thanks to the increased chemotherapeutic options in patients with metastatic colorectal cancer (mCRC), the overall survival has significantly improved the last decade. Liver failure is a common cause of death in mCRC with liver metastases. Therefore in these patients locoregional treatment is a valuable treatment option in order to increase survival. In this review we provide insights on the published literature.